


# NanoForm Cardiovascular Therapeutics Limited

Unaudited Abbreviated Accounts

For the year ended 31 December 2015

TUESDAY



\*L5Z9BMNE\*

L10

31/01/2017

#30

COMPANIES HOUSE

# NanoForm Cardiovascular Therapeutics Limited

## Contents

---

	Page
Abbreviated balance sheet	1
Notes to the abbreviated accounts	2 - 3

---

# NanoForm Cardiovascular Therapeutics Limited

## Abbreviated Balance Sheet

As at 31 December 2015

	Notes	2015 £	£	2014 £	£
<b>Fixed assets</b>					
Investments	2		307,307		307,307
<b>Current assets</b>					
Debtors		7,475		6,216	
Cash at bank and in hand		13		2,186	
		<u>7,488</u>		<u>8,402</u>	
<b>Creditors: amounts falling due within one year</b>		<u>(15,730)</u>		<u>(5,181)</u>	
<b>Net current liabilities/(assets)</b>			<u>(8,242)</u>		<u>3,221</u>
<b>Total assets less current liabilities</b>			<u>299,065</u>		<u>310,528</u>
<b>Capital and reserves</b>					
Called up share capital	3		10,000		10,000
Share premium account			348,920		348,920
Profit and loss account			(59,855)		(48,392)
<b>Shareholders' funds</b>			<u>299,065</u>		<u>310,528</u>


For the financial year ended 31 December 2015 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These abbreviated financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

Approved by the Board for issue on 17.01.17



Mr László Tibor Ürgé  
Director

Company Registration No. 07203553

# NanoForm Cardiovascular Therapeutics Limited

## Notes to the Abbreviated Accounts

For the year ended 31 December 2015

### 1 Accounting policies

#### 1.1 Accounting convention

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

The company meets its day to-day working capital requirements with the support of fellow group companies. DBH Investment Kockázati Tőkealap Kezelő Zrt. ("DBH Investment"), a fully owned subsidiary of DBH Group B.V., has confirmed that it will support the company for at least 12 months from the date of sign off of the company accounts.

#### 1.2 Compliance with accounting standards

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), which have been applied consistently (except as otherwise stated).

#### 1.3 Turnover

Turnover represents amounts receivable for goods and services net of VAT and trade discounts.

#### 1.4 Investments

Fixed asset investments are stated at cost less provision for diminution in value.

#### 1.5 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.

### 2 Fixed assets

	Investments £
<b>Cost</b>	
At 1 January 2015 & at 31 December 2015	307,307
At 31 December 2014	307,307

#### Holdings of more than 20%

The company holds more than 20% of the share capital of the following companies:

Company	Country of registration or incorporation	Shares held Class	%
<b>Subsidiary undertakings</b>			
Nanoform Magyarország Kutató-Fejlesztő Kft	Hungary	Ordinary	74.10

# NanoForm Cardiovascular Therapeutics Limited

## Notes to the Abbreviated Accounts (Continued)

For the year ended 31 December 2015

### 2 Fixed assets

(Continued)

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows:

		Capital and reserves	Profit/(loss) for the year
		2015	2015
		£	£
	Principal activity		
Nanoform Magyarország	Research & Development		
Kutató-Fejlesztő Kft		152	(31)
		<u>152</u>	<u>(31)</u>
<b>3 Share capital</b>		<b>2015</b>	<b>2014</b>
		£	£
<b>Allotted, called up and fully paid</b>			
4,120 ordinary shares of £1 each		4,120	4,120
5,880 ordinary shares 2 of £1 each		5,880	5,880
		<u>10,000</u>	<u>10,000</u>

### 4 Control

The parent company is Kowork Seedstar Incubation Zártkörűen Működő Részvénytársaság, a closed public limited company established under Hungarian law. Kowork Seedstar Incubation Zrt. is owned by DBH Investment Venture Capital Fund ("DBH Fund"). The Hungarian government holds 70% of DBH fund.